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Summary
Objective: To characterize the time course of aggrecan and type II collagen degradation in the rat iodoacetate model of cartilage degeneration
in relationship to the temporal sequence that has been described in human osteoarthritis (OA).
Design: Rats were injected intra-articularly in one knee joint with iodoacetate and damage to the tibial plateau was assessed from digitized
images captured using an image analyzer. The articular cartilage from the tibial plateau was harvested, extracted and glycosaminoglycan
(GAG) content was measured using the dimethylmethylene blue (DMMB) assay. Cartilage aggrecan neoepitopes were detected in cartilage
extracts by Western blotting using antibodies recognizing the aggrecanase-generated C-terminal neoepitope NITEGE (BC-13) and the MMP-
generated C-terminal neoepitope DIPEN (BC-4). A type II collagen collagenase-generated neoepitope was detected in cartilage extracts by
ELISA using the Col2-3/4Cshort antibody; denatured collagen was detected using the Col2-3/4m antibody.
Results: Degenerative joint changes and proteoglycan (GAG) loss progressed with time after iodoacetate injection. Western blotting of
cartilage extracts of iodoacetate treated rats demonstrated an increase in both aggrecanase- and MMP-generated epitopes with the NITEGE
aggrecanase neoepitope being signiﬁcantly elevated on days 7, 14 and 21 while DIPEN the MMP neoepitope was signiﬁcantly elevated on
days 7 and 14. The type II collagen neoepitope recognized by Col2-3/4Cshort was signiﬁcantly increased in cartilage extracts of rats at days
14 and 21 after iodoacetate injection.
Conclusion: The proteoglycan fragments extracted from the knee cartilage of rats after the intra-articular injection of iodoacetate appeared to
result from cleavage at both aggrecanase and MMP sites. Cleavage of type II collagen by collagenase was also detected after iodoacetate
injection and occurred subsequent to the initiation of aggrecan loss. These observations serve to demonstrate similarities in the mechanisms
of cartilage degeneration induced by iodoacetate to those seen in articular cartilage in OA.
 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a degenerative disease that occurs in
a large proportion of the elderly and is characterized by
cartilage matrix degradation. The degradation of cartilage
that occurs in OA is a result of proteolytic cleavage of both
of its structural components, aggrecan and type II collagen.
The degradation of aggrecan occurs early in the process of
cartilage degeneration1 and is followed by the catabolism of
collagen ﬁbrils leading to the loss of cartilage structural
integrity2. The loss of aggrecan from cartilage is believed to
be due to the proteolytic cleavage within the interglobulin
domain (IGD) between the G1 and G2 globular domains at
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number of MMPs have been shown to cleave at the Asn341-
Phe342 (references 3e5) while the cleavage of the Glu373-
Ala374 is due to ‘‘aggrecanase’’ enzymatic activity6e9.
ADAMTS-4 and ADAMTS-5 were the ﬁrst aggrecanases
to be identiﬁed and are members of the A Disintegrin And
Metalloproteinase with ThromboSpondin motifs gene fam-
ily10,11. More recently, a third ADAMTS (ADAMTS-1) has
been shown to cleave aggrecan at the sites appropriate to
classify it as an ‘‘aggrecanase’’12, while ADAMTS-9 has
been shown to cleave one of the C-terminal aggrecanase
sites albeit inefﬁciently13.
Type II collagen is the major structural collagen in
articular cartilage. A number of MMPs (MMPs 1, 8, 13, 14
and 18) cleave intact collagen between residues Gly775 and
Leu776. Neoepitope antibodies that recognize the carboxy-
terminal neoepitope of this cleavage site have been
developed14 as well as antibodies to denatured collagen15.
These antibodies have been used to demonstrate in-
creased collagen cleavage and degradation in human and
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neoepitopes generated in aggrecan by the enzymatic
activity of MMPs and aggrecanases have been developed
and have been used in experimental systems of cartilage
degradation18e20.
Although the etiology of OA is poorly understood,
numerous animal models that mimic aspects of the disease
have been developed to study the pathophysiology of the
disease and to evaluate potential therapeutics. Kalbhen and
Blum ﬁrst described the iodoacetate-induced model of
degenerative arthritis in chickens21 and subsequently the
model was performed in a number of other species22e26.
The severity of the cartilage lesions, suppression of mobility
and inhibition of proteoglycan synthesis were directly
related to the dose of iodoacetate27. Recently, we have
demonstrated the upregulation of MMPs in knee cartilage
from iodoacetate-injected rats and inhibition of the de-
generative changes by several MMP inhibitors28. In the
present study we have investigated the mechanisms of
cartilage degeneration in the rat iodoacetate model by
exploring the temporal relationship between MMP- and
aggrecanase-generated aggrecan metabolism as well as
aggrecan and type II collagen cleavage in cartilage
degradation using neoepitope speciﬁc antibodies.
Materials and methods
ANIMALS
SpragueeDawley male rats weighing 220e230 g
(Harlan, Indianapolis, IN) were housed singly in wire cages
in sanitary ventilated animal rooms with controlled tem-
perature, humidity and regular light cycles. Rodent chow
(Ralston-Purina, Richmond, IN) and water were available
ad libitum. Animals were acclimated for at least 1 week
before use.
All animals were housed, fed, and handled in compliance
with the standards set forth by the Animal Welfare Act as
amended. Where standards are not indicated in the Animal
Welfare Act the recommendations on HHS Publications
(NIH) No. 85-23, ‘‘Guide for the Care and Use of Laboratory
Animals’’, were followed.
INDUCTION OF IODOACETATE-INDUCED ARTHRITIS
Arthritis was induced by a single intra-articular injection of
iodoacetate into the knee joint of rats anesthetized using
(3:1) CO2/O2. A 10 mg/ml concentration of monosodium
iodoacetate (MIA) (Aldrich Chemical, Milwaukee, WI) was
prepared using injectable saline as the vehicle. After
appropriate anesthesia each rat was positioned on its back
and the left leg was ﬂexed 90 degrees at the knee. The
patellar ligament was palpated below the patella and the
injection was made into this region. Each rat received
0.025 ml intra-articular injection into the left knee using
a glass gas tight syringe with a 27 gauge 12 inch needle.
Care was taken not to advance the needle in too far into the
cruciate ligaments.
Since only a small amount of cartilage is obtained from
rat knees and different extraction protocols are required for
aggrecan and collagen analysis, two separate experiments
were performed. One experiment was used for processing
knee cartilage for aggrecan analysis and a second exper-
iment for collagen analysis as described below. Each
experiment utilized groups of 10 rats sacriﬁced 0, 1, 3, 7, 14
and 21 days after iodoacetate injection for a total of 60 ratsfor each experiment. The left knees of the sacriﬁced
animals were disarticulated and the tibial plateau imaged
using an Optimas image analyzer. The tibial plateau was
used for image analysis because it provided a relatively ﬂat
surface compared with the femoral condyles, allowing the
image analysis camera to focus on the entire cartilage
surface. The severity of damage in the magniﬁed images
was assessed by three independent observers in a blinded
manner using a scale of increasing severity (0Znormal;
4Zmaximum severity) as described previously28.
ANALYSIS OF AGGRECAN METABOLISM
Articular cartilage was harvested from the tibial plateau of
rats at various times after iodoacetate injection. The
cartilage from 10 rats at each time point was randomly
pooled into ﬁve groups containing cartilage from two rats to
provide sufﬁcient material for quantitation of proteoglycan
and for Western blots. The cartilage was blotted dry,
weighed and extracted with 4 M GuHCl in 0.05 M sodium
acetate containing the proteinase inhibitors 0.01 M EDTA,
0.1 M 6-aminohexanoic acid, 0.005 M benzamidine HCl
and 0.01 M N-ethylmaleimide for 48 h at 4(C. Following
extraction the cartilage residue was digested with papain
and the proteoglycan content of the cartilage extract and
papain digest was measured as sulphated glycosaminogly-
can (GAG) using a dimethylmethylene blue assay29 with
chondroitin sulphate-C from shark cartilage (Sigma Chem-
ical, Inc., St Louis, MO) as standard.
Proteoglycan fragments in the guanidine extracts of
cartilage from the GAG studies outlined above were
analyzed as described previously19. There were ﬁve pools
of cartilage at each time point containing cartilage from two
rats. One set of samples was used to work out experimental
conditions (antibody concentration loading amounts) and
the other four samples were used to run four separate
Western blots. Brieﬂy, the guanidine extracts were dialyzed
and deglycosylated with chondroitinase ABC (Sigma Inc.),
keratanase (Seikagaku) and keratanase II (Seikagaku) at
37(C for 2e4 h. Samples were dialyzed against deionized
water, lyophilized and separated under reducing conditions
on 4e12% gradient Tris/glycine SDS-PAGE gels (Novex,
Inc., Frankfurt, Germany). Samples were loaded such that
the extract from an equal wet weight of cartilage was run in
each lane. The proteins were electrophoretically transferred
to nitrocellulose membranes. Immunoblotting was per-
formed as previously described30 using monoclonal anti-
bodies recognizing the C-terminal aggrecan neoepitope
NITEGE (BC-13)18 and the MMP-generated C-terminal
aggrecan neoepitope VDIPEN (BC-4)18. Blots were digi-
tized and the density of immunostained bands was
quantiﬁed using NIH image software. The band with the
highest density on each Western blot was assigned a value
of 100 density units and the densities of all other bands
were compared to the 100 unit band. This allowed the
comparison between different Western blots.
EXTRACTION OF RAT ARTICULAR CARTILAGE FOR QUANTITATION
OF COLLAGENASE CLEAVAGE NEOEPITOPE AND DENATURED
TYPE II COLLAGEN
Articular cartilage was harvested from the tibial plateau
rats at various times after iodoacetate injection, blotted dry,
weighed and extracted overnight at 37(C with a-chymo-
trypsin (w0.3 mg/15 mg of cartilage) in 50 mM TriseHCl,
pH 7.6, containing 1 mM EDTA, 1 mM iodoacetamide and
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described14,15. The a-chymotrypsin activity was inhibited by
incubating for 20 min at 37(C with N-tosyl-L-phenylalanine-
chloromethyl ketone (TPCK; Sigma Chemical Co.) at a ﬁnal
concentration of 160 mg/ml. The samples were then
centrifuged and the supernatants were assayed using an
ELISA assay for the Col2-3/4Cshort neoepitope14 and for
denatured collagen using the mouse monoclonal antibody
(Col2-3/4m) to the interchain epitope CB11B15. The
remaining insoluble portion of the cartilage was digested
overnight at 56(C with 1 mg/ml proteinase K in 50 mM
TriseHCl containing the proteinase inhibitors described
above. Proteinase K was inactivated by boiling for 20 min.
The percent collagen cleaved was calculated from
the amount of Col2-3/4Cshort neoepitope assayed in the
chymotrypsin extract expressed as a percentage of the total
collagen content (total Col2-3/4m epitope in chymotrypsin
and proteinase K extracts).
STATISTICAL ANALYSIS
Quantitative data from the GAG and aggrecan neo-
epitope studies were analyzed using ANOVA and data from
the collagen degradation studies were evaluated using
a non-homogeneous analysis of variance model.
Results
CARTILAGE AND MATRIX DEGRADATION INCREASE WITH TIME
AFTER IODOACETATE INJECTION
Tibial degeneration
The injection of 0.25 mg of iodoacetate into the left knee
of rats resulted in a time related increase in the severity of
cartilage degeneration as revealed by image analyses of
the tibial plateau. There was virtually no macroscopic
cartilage degeneration until 7 days after iodoacetate in-
jection and then cartilage damage progressed from days
7 to 21 (Fig. 1).
Aggrecan loss and degeneration in tibial plateau
There was a decrease in extractable GAG in the cartilage
from the iodoacetate-injected knees with time (Fig. 2).
There was no signiﬁcant change in GAG content on days
1 and 3 after iodoacetate injection compared to the day 0
animals; however, there was a signiﬁcant decrease in GAG
content on days 7, 14 and 21 (P!0:001) (Fig. 2). The GAG
content on day 21 was signiﬁcantly lower than that on all
other days (P!0:002). The change in GAG content was
consistent with the increase in the cartilage damage scores.
Tibial cartilage extracted from the knee joint of rats at
various times after iodoacetate injection was analyzed by
Western blotting using antibodies to neoepitopes generated
at the aggrecan cleavage sites produced by aggrecanase
(NITEGE) or MMPs (DIPEN). A 70 kDa doublet and a single
50 kDa protein were the two predominant NITEGE termi-
nating G1 fragments [Fig. 3(A)]. The 70 kDa doublet was
consistent with that observed in other species19. While we
have not previously observed a 50 kDa terminating
catabolite, it is consistent in size with a minor band detected
in extracts of retinoic acid treated human articular carti-
lage31. The full range of proteins present in a pool of
cartilage extracts from all time points is shown in Fig. 3(B),
lane 1. Western blot analysis of the cartilage extractexcluding the primary antibody demonstrated that this band
was speciﬁc [Fig. 3(B), lane 2] and both the 50 and 70 kDa
bands were observed when a duplicate ﬁlter was probed
with a polyclonal anti-NITEGE serum ( generously provided
by Dr John Mort, Shriners Hospital, Quebec, Canada)
[Fig. 3(B), lane 3]. The 50 kDa NITEGE terminating
fragment was present in the day 0 samples and must have
resulted from earlier catabolism and accumulation during
the rats’ lifetime. A single DIPEN terminating aggrecan
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Fig. 1. Time-dependent effect of the injection of iodoacetate on the
severity of tibial plateau degeneration in rat knees. The severity of
knee joint degeneration in rats injected with 0.25 mg of iodoacetate
was evaluated at varying times after injection and the cartilage was
collected for biochemical evaluation of aggrecan degradation. The
severity of damage to the tibial plateau was assessed using
magniﬁed images captured with an image analyzer using a scale of
increasing severity (0Znormal; 4Zmaximum severity) as de-
scribed in Materials and Methods. The data are presented as
meanGS.E.M. from 10 rats per group.
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Fig. 2. Time-dependent loss of glycosaminoglycan (s-GAG) after
intra-articular injection of iodoacetate into the knee of rats. The s-
GAG content of knee cartilage from rats at various times after
iodoacetate injection (shown in Fig. 1) was measured using the
dimethylmethylene blue method. The cartilage from 10 rats at each
time point was randomly pooled into ﬁve groups containing
cartilage from two rats and the data are presented as the
meanGS.E.M. (N ¼ 5) amount of GAG/mg of wet weight of cartilage.
*Denotes signiﬁcance (P!0:05) compared to day 0.
723Osteoarthritis and Cartilage Vol. 12, No. 9Fig. 3. Western blot analysis of cartilage extracts from rats at various times after iodoacetate injection (shown in Fig. 1). Cartilage was collected
at various times after iodoacetate injection and immunoblotted with antibodies recognizing the aggrecanase-generated NITEGE and MMP-
generated DIPEN terminating aggrecan neoepitopes. The results from a single Western blot representative of four individual Western blots are
shown (A). As a control for the speciﬁcity of the primary antibody (BC-13) a Western blot of pooled joint extracts was developed without BC-13
(B, lane 2) or with a polyclonal anti-NITEGE ( generously provided by Dr John Mort) (B, lane 3). (B, lane 1) shows a coomassie stain of the full
range of proteins present in the cartilage extract. The relative amount of each epitope was measured by densitometry (C). The data are
presented as meanGS.E.M. from the four Western blots. The 70 kDa doublet C-terminal NITEGE protein is shown as an open bar, the 50 kDa
C-terminal NITEGE protein as a hatched bar and the C-terminal DIPEN terminating 55 kDa protein as a solid black bar.metabolite (w55 kDa) was observed in the rat cartilage and
was similar in size to that seen in other species [Fig. 3(A)]19.
The intensity of the NITEGE bands changed signiﬁcantly
with time as determined by densitometry. The density of
both the 70 and 50 kDa NITEGE bands was signiﬁcantly(P!0:01) increased compared with day 0 on days 7, 14
and 21 [Fig. 3(C)]. The staining intensity of the DIPEN band
also changed signiﬁcantly with time. The increased staining
observed on day 3 did not reach statistical signiﬁcance,
whereas the staining observed at days 7 and 14 was
724 M. J. Janusz et al.: Cartilage neoepitopes in iodoacetate-induced arthritissigniﬁcantly greater than that observed at day 0 [Fig. 3(C)].
Interestingly, the staining intensity of the DIPEN band
decreased at day 21 and was not signiﬁcantly different from
day 0.
COLLAGEN CLEAVAGE INCREASES WITH TIME AFTER
IODOACETATE INJECTION
Since only a small amount of cartilage is obtained from
rat knees and a different extraction protocol was required
for assessment of collagen cleavage a separate rat
iodoacetate experiment was performed. Rats were sacri-
ﬁced at various times after a single intra-articular injection of
0.25 mg of iodoacetate into the left knee; the severity of
arthritis was determined and the tibial cartilage was
extracted for quantitation of collagen neoepitopes. Although
there was a time related increase in the severity of cartilage
degeneration as assessed by gross pathology using image
analysis (Fig. 4), the amount of Col2-3/4C neoepitope
present in cartilage did not signiﬁcantly increase during the
ﬁrst week after iodoacetate injection but was signiﬁcantly
elevated on days 14 and 21 (P!0:01) compared to day 0
controls (Fig. 5).
The percentage of denatured collagen as measured with
the Col2-3/4m antibody was signiﬁcantly higher than the
Col2-3/4Cshort epitope in both control rats and iodoacetate-
injected animals (Fig. 5). However, the Col2-3/4m epitope
was not signiﬁcantly higher on days 14 and 21 compared to
day 0 controls (Fig. 5).
Discussion
We have shown that progressive degeneration of
articular cartilage develops in the knees of rats following
intra-articular injection of iodoacetate. In association with
this degeneration, the cartilage contains an increased
content of aggrecan epitopes reﬂecting an increase in both
aggrecanase- and MMP-generated cleavage. The loss of
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Fig. 4. Time-dependent effect of the injection of iodoacetate on the
severity of joint degeneration in rat knees. The severity of tibial
articular cartilage degeneration in rats injected with 0.25 mg of
iodoacetate was evaluated at varying times after injection and the
cartilage was collected for biochemical evaluation of collagen
degradation. The data are presented as meanGS.E.M. from 10 rats
per group.aggrecan as detected by GAG content of the extracted
cartilage increased with time in the rat iodoacetate model
and the appearance of both aggrecanase and MMP
neoepitopes was temporally related to the aggrecan loss
with both epitopes signiﬁcantly elevated at day 7. We also
found that type II collagen undergoes increased cleavage
by collagenase as reﬂected by the increase in the amount of
neoepitope detected by the Col2-3/4Cshort antibody in
iodoacetate-injected rats. However, this increase was
clearly observed subsequent to the increase in proteogly-
can loss and cleavage as has been shown in culture32. The
data suggest that both aggrecanase and MMPs play a role
in the cartilage degradation that occurs in the iodoacetate
model.
In the present study we have utilized detection of the
neoepitope sequences NITEGE and DIPEN to indicate
aggrecanase or MMP cleavage of the aggrecan interglob-
ular domain, respectively. Although MMP-8 can cleave at
the aggrecanase site to generate NITEGE neoepitope, this
only occurs after prolonged cleavage and is therefore
considered unlikely to account for generation of this
neoepitope in vivo33. Similarly, although cathepsin B can
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Fig. 5. Time course of type II collagen cleavage in the rat
iodoacetate-induced arthritis model. Articular cartilages from rat
knees harvested at various times after iodoacetate injection (shown
in Fig. 4) were extracted with a-chymotrypsin and assayed for Col2-
3/4Cshort and Col2-3/4m epitopes as described in Materials and
Methods. Data are expressed as % cleavage of type II collagen
(Col2-3/4Cshort; A) or as % collagen denaturation (Col2-3/4m; B) in
chymotrypsin extracts of cartilage as a percent of total collagen
content and the mean is shown as a horizontal line. Total collagen
content was determined by the sum of the Col2-3/4m epitope from
the chymotrypsin and proteinase K extracts. *Denotes statistical
signiﬁcance at P > 0:05.
725Osteoarthritis and Cartilage Vol. 12, No. 9generate the DIPEN epitope in vitro through its exo-
peptidase activity, the acidic pH (!6.0) necessary for this
reaction to proceed efﬁciently suggests that it may not be
physiologically relevant34. Most recently, recombinant
ADAMTS-4 was shown to generate the DIPEN epitope in
solution phase digests of puriﬁed aggrecan in vitro35.
However, using a different recombinant ADAMTS-4 or
recombinant ADAMTS-1 or ADAMTS-5, cleavage at this
classical MMP site was not found by other workers36.
Numerous studies have also failed to demonstrate in-
creased generation of DIPEN when cartilage explants are
stimulated with a variety of catabolic agents in vitro, despite
marked increases in aggrecanase activity and depletion of
cartilage aggrecan19,37,38. These results suggest that
generation of the DIPEN neoepitope by ADAMTS-4 may
not be relevant in cartilage tissue in vivo. We therefore
consider it reasonable to continue to ascribe the generation
of the NITEGE and DIPEN epitopes in cartilage to the
action of aggrecanases and MMPs, respectively.
In our previous study we demonstrated that administra-
tion of MMP inhibitors for the ﬁrst 7 days following
iodoacetate injection was able to signiﬁcantly ameliorate
the cartilage damage28. It may seem difﬁcult to reconcile
with the present data demonstrating that collagenase
cleavage of collagen is not maximal until days 14e21
[Fig. 5(A)]. One possible explanation is that MMP activity in
the early phases of iodoacetate-induced disease is re-
sponsible for the cleaving matrix components that bind to
type II collagen and normally act to protect the ﬁbril from
catabolism. Using in vitro models of progressive cartilage
breakdown, it has been shown that COMP and ﬁbromodulin
are cleaved by metalloproteinases and released from
cartilage prior to subsequent collagenolysis39,40. Inhibiting
the catabolism of these or other ﬁbril-associated molecules
such as decorin, biglycan or collagen type IX during the ﬁrst
week of iodoacetate-induced arthritis could stop or delay
subsequent collagen proteolysis. Additionally, the early
administration of MMP inhibitors in this disease model may
prevent the initial activation of proteinases such as MMP-3
that are required for collagenase activation. In our previous
study, analysis of cartilage collagenase and gelatinase was
performed in such a way that we did not distinguish
between active and proenzyme28. Abrogation of early
MMP activity may also stop the catabolism of other matrix
molecules such as ﬁbronectin, fragments which could then
stimulate aggrecanase and collagenase synthesis and
activity38,41.
Our results demonstrating the presence of MMP- and
aggrecanase-generated cleavage fragments in the rat
iodoacetate model using biochemical methodology are
similar to those recently reported for several rodent models
of OA using immunohistochemistry. In mice containing a
transgene overexpressing active MMP-13 in their hyaline
cartilage signiﬁcant upregulation of pericellular and in-
tracellular staining of chondrocytes for the Col2-3/4Cshort
epitope was observed17. Collagen cleavage detected using
the antibody Col2-3/4Cshort was also associated with
histopathologic lesions in the STR/ORT model of OA in
mice42 and in ﬁbrillated areas after anterior cruciate
transection in the rat43. Similarly, the aggrecan degradation
epitopes generated by MMPs (VDIPEN) and aggrecanase
(NITEGE) colocalized in both the pericellular and matrix
adjacent to OA lesions in the mouse STR/ORT model44.
The presence of both MMP- and aggrecanase-generated
aggrecan fragments has been detected in human articular
cartilage from normal and OA patients45. In extracts of
human osteoarthritic articular cartilage signiﬁcantly moreCol2-3/4Cshort epitope was detected than in nonarthritic
human cartilage around chondrocytes16. Although both
aggrecan and collagen degradation neoepitopes generated
in the rat iodoacetate model were also observed in
spontaneous and surgically induced rodent models (ACL)
the distribution and amount of these epitopes may vary.
Matrix degradation occurs rapidly and is widespread in the
rat iodoacetate model, whereas damage is more focal,
generally less severe and develops more slowly in the STR/
ORT and rat ACL models.
Due to the difﬁculty in obtaining signiﬁcant amounts of
synovial ﬂuid from rat knees in the iodoacetate model, the
present study relied on extraction of rat cartilage and only
detected fragments that remained in the tissue after being
cleaved by MMPs or aggrecanase. Therefore, any aggre-
can G1 fragment that diffused into the synovial ﬂuid
remained undetected. The presence of DIPEN C-terminal
G1 epitopes in the rat cartilage could have resulted from the
primary cleavage of aggrecan by MMPs or MMP truncation
of G1 fragments originally cleaved at the aggrecanase
NITEGE site. However, the presence of DIPEN epitope is
consistent with the previously reported28 presence of MMP
activity in cartilage extracts after the injection of iodoace-
tate. The simultaneous presence of both NITEGE and
DIPEN epitopes in the rat iodoacetate model differs from
that observed in several animal models of rheumatoid
arthritis where NITEGE was the prominent epitope early
during aggrecan depletion, whereas DIPEN dominated
during the collagen degradation phase46. However, both
DIPEN and NITEGE epitopes colocalized in human OA
lesions45 and in spontaneous OA in mice44. These studies
may suggest that the temporal relationship between
aggrecanase and MMP activity in models of inﬂammatory
arthritis in mice and naturally occurring OA in mice and man
may differ.
The amount of collagen cleavage fragment detected in rat
cartilage extracts by the Col2-3/4Cshort antibody increased
almost threefold from day 0 to day 21 after iodoacetate
injection. This increase was similar to that observed in
articular cartilage extracts from OA patients compared to
normals14. The percent of collagen cleavage epitope
detected on Western blot using Col2-3/4Cshort at day 21
was 0.49% (Fig. 5) which is comparable to approximately
1.5% of this epitope detected in OA patients14. The amount
of denatured collagen observed in the rat iodoacetate
model using the Col2-3/4m antibody increased about 2e3%
from day 0 to day 21. The relatively low quantity of Col2-3/
4Cshort epitope detected in the arthritic animals in the
present study as well as previous human studies14 could be
an underestimation due to enzymatic cleavage of the
collagen by proteinases such that the Col2-3/4Cshort
antibody neoepitope is degraded and/or released, whereas
the Col2-3/4m epitope is relatively distant from the
collagenase cleavage site and may be less susceptible to
secondary cleavage and more likely to be retained in the
matrix.
Aggrecanase cleavage as detected using an antibody to
the NITEGE epitope in cartilage from iodoacetate-injected
rats resulted in a 70 kDa doublet on Western blot that was
consistent with observations in other species19. The 50 kDa
band observed must have resulted from further proteolysis
in the N-terminus of the G1 molecule without affecting the
hyaluronic acid binding as it is retained in the cartilage. It is
possible that there is a cleavage in one of the three
disulphide bonded N-terminal loops that does not affect
hyaluronic acid binding. The small N-terminal peptide that is
presumably removed to generate this 50 kDa NITEGE
726 M. J. Janusz et al.: Cartilage neoepitopes in iodoacetate-induced arthritiscatabolite is most likely disulphide bonded and part of an
intact G1. However, as all the gels are run under reducing
conditions, this small peptide is released. The 50 kDa
NITEGE terminating fragment was present in the day 0
samples and must have resulted from earlier catabolism
and accumulation during the rats’ lifetime. While this
fragment has been generated by aggrecanase cleavage
of the IGD, the enzyme responsible for the further
N-terminal cleavage is unknown.
The decrease in DIPEN in cartilage extracts at day 21 in
the present study appears to contradict the increase in
collagenase-generated Col2-3/4Cshort epitope. However,
a similar loss of DIPEN immunostaining was recently
reported in the most degenerate cartilage in a mouse model
of OA47. This late stage decrease in DIPEN may be
explained by the release of G1 from the cartilage as the
collagen network becomes more severely disrupted, ac-
counting for the coordinate loss of NITEGE immunostaining
in the most degenerate mouse cartilage47 and the decrease
in the 70 kDa NITEGE bands in the present study (Fig. 3).
In contrast, there was no decrease in the 50 kDa NITEGE
band in the cartilage extracts at day 21. This smaller
NITEGE catabolite may only be generated through the
action of aggrecanase and a second cell-associated
proteinase. Therefore, as the cartilage degeneration pro-
gresses and the interterritorial matrix is lost, only pericellular
newly synthesized aggrecan remains and generation of the
50 kDa but not 70 kDa NITEGE continues.
These results suggest that degradation of aggrecan in the
rat iodoacetate model involves the enzymatic activities of
both aggrecanases and MMPs. Furthermore, type II
collagen cleavage as measured using the Col2-3/4Cshort
antibody was also increased in the knee cartilage of
iodoacetate-injected rats suggesting a role for MMPs of
the collagenase subtype. The demonstration of an increase
in cleavage neoepitopes generated by aggrecanase(s) and
MMPs in articular cartilage in the rat iodoacetate model
associated with cartilage degeneration serves to reveal the
similarities in the pathological mechanisms observed in this
model to that seen in articular cartilage in human OA. The
cleavage of type II collagen appears temporally after the
degradation of aggrecan, similar to observations made in
cultured bovine articular cartilage degradation induced by
interleukin-1a32.
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